TY - JOUR
T1 - Nanoparticles for cancer imaging
T2 - The good, the bad, and the promise
AU - Chapman, Sandra
AU - Dobrovolskaia, Marina
AU - Farahani, Keyvan
AU - Goodwin, Andrew
AU - Joshi, Amit
AU - Lee, Hakho
AU - Meade, Thomas
AU - Pomper, Martin
AU - Ptak, Krzysztof
AU - Rao, Jianghong
AU - Singh, Ravi
AU - Sridhar, Srinivas
AU - Stern, Stephan
AU - Wang, Andrew
AU - Weaver, John B.
AU - Woloschak, Gayle
AU - Yang, Lily
N1 - Funding Information:
This project has been funded in whole or in part with federal funds from the National Cancer Institute (NCI)–NIH under contract number HHSN261200800001E. All authors are part of the NCI Alliance for Nanotechnology in Cancer and hold either Center of Cancer Nanotechnology Excellence or Cancer Nanotechnology Platform Partnership grants. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Funding Information:
Dr. Rao received his BS in Chemistry from Peking University, China, in 1991, a PhD. in Chemistry from Harvard University in 1999 under the guidance of Professor George M. Whitesides, and a Damon Runyon Cancer Research Foundation postdoctoral fellowship at UCSD with Professor Roger Y. Tsien. He began his assistant professorship in the Department of Molecular and Medical Pharmacology at UCLA in 2002, and currently an Associate Professor of Radiology and Chemistry at Stanford University. His research interests include molecular probes, cancer imaging, bionanotechnology, biosensing, and chemical biology.
PY - 2013/10
Y1 - 2013/10
N2 - Recent advances in molecular imaging and nanotechnology are providing new opportunities for biomedical imaging with great promise for the development of novel imaging agents. The unique optical, magnetic, and chemical properties of materials at the scale of nanometers allow the creation of imaging probes with better contrast enhancement, increased sensitivity, controlled biodistribution, better spatial and temporal information, multi-functionality and multi-modal imaging across MRI, PET, SPECT, and ultrasound. These features could ultimately translate to clinical advantages such as earlier detection, real time assessment of disease progression and personalized medicine. However, several years of investigation into the application of these materials to cancer research has revealed challenges that have delayed the successful application of these agents to the field of biomedical imaging. Understanding these challenges is critical to take full advantage of the benefits offered by nano-sized imaging agents. Therefore, this article presents the lessons learned and challenges encountered by a group of leading researchers in this field, and suggests ways forward to develop nanoparticle probes for cancer imaging.
AB - Recent advances in molecular imaging and nanotechnology are providing new opportunities for biomedical imaging with great promise for the development of novel imaging agents. The unique optical, magnetic, and chemical properties of materials at the scale of nanometers allow the creation of imaging probes with better contrast enhancement, increased sensitivity, controlled biodistribution, better spatial and temporal information, multi-functionality and multi-modal imaging across MRI, PET, SPECT, and ultrasound. These features could ultimately translate to clinical advantages such as earlier detection, real time assessment of disease progression and personalized medicine. However, several years of investigation into the application of these materials to cancer research has revealed challenges that have delayed the successful application of these agents to the field of biomedical imaging. Understanding these challenges is critical to take full advantage of the benefits offered by nano-sized imaging agents. Therefore, this article presents the lessons learned and challenges encountered by a group of leading researchers in this field, and suggests ways forward to develop nanoparticle probes for cancer imaging.
KW - Cancer
KW - Detection
KW - Imaging
KW - Nanomedicine
KW - Screening
UR - http://www.scopus.com/inward/record.url?scp=84886947107&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84886947107&partnerID=8YFLogxK
U2 - 10.1016/j.nantod.2013.06.001
DO - 10.1016/j.nantod.2013.06.001
M3 - Article
C2 - 25419228
AN - SCOPUS:84886947107
SN - 1748-0132
VL - 8
SP - 454
EP - 460
JO - Nano Today
JF - Nano Today
IS - 5
ER -